We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Microfluidic Chip Enables Simultaneous Diagnosis of COVID-19 and Influenza Diseases

By LabMedica International staff writers
Posted on 06 Jan 2022

A research team has developed a microfluidic chip that is capable of simultaneous diagnosis of COVID-19 and influenza diseases, by applying the microfluidic chip technologies. More...

Researchers from the Toyohashi University of Technology (Toyohashi, Japan) and Jikei University School of Medicine (Tokyo, Japan) built a theoretical model that manipulates microfluidic flow with an extremely simple microchannel design and has established an optimal design theory for microfluidic chips. Further, by using the diagnostic device they developed, they performed genetic amplification experiments on four types of infectious diseases, including COVID-19, and demonstrated that multiplexed rapid and simultaneous diagnosis was possible within 30 minutes. The device can be utilized for genetic diagnoses in a range of fields (e.g. agriculture, farming, and fisheries industries, food industry, and health and medical care), not only human infectious diseases. The diagnostic technology can enable anyone, anywhere, any time to detect viral diseases in a rapid, simple, and low-cost way.

The LAMP (Loop-Mediated Isothermal Amplification) method is a genetic test technology. This simple test method does not require an expensive accurate temperature control equipment, etc., in contrast to the widespread PCR test, and can be conducted on site because it allows genetic amplification at a constant temperature for a constant length of time (60 to 65℃, 30 minutes to an hour or so). However, to diagnose multiple types of viruses, the conventional LAMP method entails considerable effort to perform as many preparations of samples and reagents and genetic amplification reactions as the number of analytes, requiring expert knowledge and skills.

Therefore, the research team developed a polydimethylsiloxane (PDMS)-based multiplexed genetic diagnostic device (size: 45mm x 25mm, reaction chamber: 3µL x 5 pieces) by applying the microfluidic chip technology. It autonomously, equally, and accurately dispenses samples and reagent into an array of reaction chambers simply by introducing the liquid, a mixture of an extremely small amount of sample extracted from the analytes and a reagent, into the diagnostic device. By heating the device in warm water (at 60 to 65℃, for 30 minutes to an hour or so), it is capable of simultaneous diagnosis of multiple types of viruses with only one operation (one work process per sample).

The genetic diagnosis result showed that four types of infectious diseases including the COVID-19 (seasonal influenza A, SARS, and influenza H1N1 pdm09) were successfully detected with this diagnosis device. Only the reaction chamber that reacted when a sample containing the gene of each virus was introduced turned sky blue (denoting a positive reaction) after 30 minutes, which means that visual detection is possible.

In addition, to support on-site diagnoses, the team has developed a smartphone app, which automatically diagnoses the reaction as positive or negative based on photographs taken with a smartphone camera. The diagnosis device is capable of easy automatic test result diagnosis (positive or negative), by placing the device after LAMP reaction in a simple LED illumination device and taking photographs with a smartphone. As a result, it is expected that anyone will be able to easily perform the test, anywhere and anytime. In the future, aiming to commercialize the diagnosis device, the research team will develop devices capable of multiplexed rapid diagnosis of variants of the COVID-19 and human infectious diseases for a safe life during and after the COVID-19 pandemic.

Related Links:
Toyohashi University of Technology 
Jikei University School of Medicine 


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Automated Clinical Chemistry Analyzer
Envoy 500+
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image: MPNST is a cancer of the connective tissue surrounding peripheral nerves, with NF1 being a key risk factor (Image Credit: Nephron/Wikimedia Commons (CC BY-SA 3.0)

Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors

Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.